Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx Adds Next-Gen Sequencing Services for Biomarker Discovery, Clinical Trial Testing

Premium

AltheaDx has added next-generation sequencing services to its clinical molecular pathology laboratory for applications in cancer biomarker discovery and clinical trial testing, the company said this week.

AltheaDx CEO Francois Ferre said in a statement that next-gen sequencing will be "highly synergistic" with the company's strategy of creating cancer-specific molecular subtype panels in partnership with Compendia Bioscience. In addition, the technology will be "highly complementary" to AltheaDx's RT-PCR-based gene expression panels.

The firm plans to provide pharmaceutical and biotechnology customers with well-characterized predictive biomarker panels of genetic polymorphisms and gene expression patterns.

Based in San Diego, AltheaDx develops and tests diagnostics. The company, which has GLP- and CLIA-certified laboratories, provides clinical biomarker discovery, assay development, and validation services.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.